Regulatory

Abliva AB publishes 2021 Annual report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Regulatory

Interim Report January-March 2020

Important events, first quarter (Jan – Mar 2020) NeuroVive proposes a 90 percent guaranteed rights issue of MSEK 74 in order to ensure that the Company has financial resources for its prioritize ...